Merrimack Pharmaceuticals (MACK) Posts Quarterly Results
Merrimack Pharmaceuticals (NASDAQ:MACK) announced its earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.15, American Banking News reports.
Shares of Merrimack Pharmaceuticals (NASDAQ:MACK) traded up 6.74% on Monday, hitting $6.97. The stock had a trading volume of 554,066 shares. Merrimack Pharmaceuticals has a 1-year low of $2.05 and a 1-year high of $8.25. The stock has a 50-day moving average of $6.52 and a 200-day moving average of $6.03. The company’s market cap is $720.7 million.
MACK has been the subject of a number of recent research reports. Analysts at Brean Capital initiated coverage on shares of Merrimack Pharmaceuticals in a research note on Tuesday, July 8th. They set a “buy” rating and a $16.00 price target on the stock. On the ratings front, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Merrimack Pharmaceuticals in a research note on Friday, June 20th. They now have a $14.00 price target on the stock, down previously from $15.00. Finally, analysts at Oppenheimer cut their price target on shares of Merrimack Pharmaceuticals from $10.00 to $8.50 in a research note on Friday, June 20th. They now have an “outperform” rating on the stock. Four investment analysts have rated the stock with a buy rating, Merrimack Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $12.88.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.